Continuum Advisory’s Castle Biosciences CSTL Stock Holding History

Continuum Advisory’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-28	Closed	-$863	–	1883
2024 Q3	$863	Buy	+28	New	+$713	﹤0.01%	1657

Other funds holding CSTL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Continuum Advisory's CSTL Position: Q4 2024 in Review

Continuum Advisory sold out of Castle Biosciences (CSTL) in Q4 2024, closing a stake of 28 shares — an estimated $863 sold.

Continuum Advisory first reported a position in CSTL in Q3 2024 and held it in 1 quarter. The position peaked at $863 in Q3 2024. 197 funds tracked by Wall St. Rank hold CSTL as of Q4 2024.

Continuum Advisory reported no remaining Castle Biosciences position as of Q4 2024 after selling out during the quarter.
Continuum Advisory sold 28 Castle Biosciences shares in Q4 2024, an estimated $863.
Continuum Advisory first reported a position in Castle Biosciences in Q3 2024 and held it in 1 quarter.
Continuum Advisory's Castle Biosciences position peaked at $863 in Q3 2024.
197 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2024.

Based on Continuum Advisory's 13F filing for Q4 2024, filed 18 Feb 2025.